Tavilermide

Tavilermide
Systematic (IUPAC) name
3-[(5S,8S,11S)-8-(4-aminobutyl)-5-(carboxymethylcarbamoyl)-16-nitro-7,10,13-trioxo-2-oxa-6,9,12-triazabicyclo[12.4.0]octadeca-1(14),15,17-trien-11-yl]propanoic acid
Clinical data
Routes of
administration		 Eye drop
Identifiers
CAS Number 263251-78-1
ATC code None
PubChem CID 9808372
ChemSpider 7984131
Chemical data
Formula C24H32N6O11
Molar mass 580.54448 g/mol

Tavilermide (INN) (developmental code name MIM-D3) is a selective, small-molecule partial agonist of TrkA, or a nerve growth factor (NGF) mimetic.[1][2][3] It was under development by Mimetogen Pharmaceuticals as an ophthalmic (eye drop) solution for the treatment of dry eyes, and reached phase III clinical trials for this indication. Tavilermide is currently being evaluated in two multi-center Phase 3 clinical studies in the United States for the treatment of dry eye disease. Tavilermide is also in phase I clinical trials for the treatment of glaucoma; studies are ongoing.[4]

See also

References

  1. ↑ Meerovitch, Karen; Torkildsen, Gail; Lonsdale, John; Goldfarb, Heidi; Lama, Teresa; Cumberlidge, Garth; Ousler III, George W. (2013). "Safety and efficacy of MIM D3 ophthalmic solutions in a randomized placebo controlled Phase 2 clinical trial in patients with dry eye". Clinical Ophthalmology: 1275. doi:10.2147/OPTH.S44688. ISSN 1177-5483.
  2. ↑ Jain, Pooja; Li, Ruihong; Lama, Teresa; Saragovi, H. Uri; Cumberlidge, Garth; Meerovitch, Karen (2011). "An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye". Experimental Eye Research 93 (4): 503–512. doi:10.1016/j.exer.2011.06.014. ISSN 0014-4835.
  3. ↑ Vickers, Laura A.; Gupta, Preeya K. (2015). "The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline". Ophthalmology and Therapy. doi:10.1007/s40123-015-0038-y. ISSN 2193-8245.
  4. ↑ Chang EE, Goldberg JL (2012). "Glaucoma 2.0: neuroprotection, neuroregeneration, neuroenhancement". Ophthalmology 119 (5): 979–86. doi:10.1016/j.ophtha.2011.11.003. PMC 3343191. PMID 22349567.

External links


This article is issued from Wikipedia - version of the Monday, November 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.